Leerink Partnrs Has Bearish Outlook for BBIO FY2028 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Analysts at Leerink Partnrs decreased their FY2028 EPS estimates for BridgeBio Pharma in a research note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn $3.14 per share for the year, down from their previous forecast of $3.50. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2029 earnings at $5.27 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.12. The business had revenue of $36.74 million for the quarter, compared to analysts’ expectations of $57.14 million. The business’s quarterly revenue was down 44.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.20) earnings per share.

BBIO has been the subject of several other research reports. Bank of America upped their price target on shares of BridgeBio Pharma from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Wednesday, June 25th. Citigroup boosted their price objective on BridgeBio Pharma from $58.00 to $67.00 and gave the stock a “buy” rating in a research note on Friday, July 11th. Piper Sandler increased their target price on shares of BridgeBio Pharma from $63.00 to $68.00 and gave the company an “overweight” rating in a research note on Monday. Scotiabank lifted their price target on BridgeBio Pharma from $52.00 to $55.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, April 30th. Finally, HC Wainwright boosted their target price on shares of BridgeBio Pharma from $53.00 to $56.00 and gave the company a “buy” rating in a research note on Monday, June 9th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $61.20.

BridgeBio Pharma Trading Down 1.5%

Shares of NASDAQ BBIO opened at $46.97 on Tuesday. The company has a market capitalization of $8.92 billion, a price-to-earnings ratio of -13.31 and a beta of 1.15. The business has a 50 day simple moving average of $39.08 and a 200-day simple moving average of $35.57. BridgeBio Pharma has a twelve month low of $21.72 and a twelve month high of $48.68.

Insiders Place Their Bets

In related news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $34.20, for a total transaction of $205,200,000.00. Following the transaction, the insider owned 13,260,971 shares in the company, valued at $453,525,208.20. This represents a 31.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Frank Mccormick sold 100,000 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $44.23, for a total transaction of $4,423,000.00. Following the sale, the director directly owned 879,979 shares in the company, valued at $38,921,471.17. This trade represents a 10.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,926,181 shares of company stock valued at $375,528,164 in the last quarter. 18.20% of the stock is currently owned by insiders.

Institutional Trading of BridgeBio Pharma

A number of institutional investors have recently bought and sold shares of BBIO. Steward Partners Investment Advisory LLC lifted its holdings in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after purchasing an additional 472 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of BridgeBio Pharma by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,306,765 shares of the company’s stock valued at $35,858,000 after purchasing an additional 21,963 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of BridgeBio Pharma during the fourth quarter worth about $456,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of BridgeBio Pharma by 25.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,530 shares of the company’s stock worth $865,000 after buying an additional 6,466 shares in the last quarter. Finally, Wealthfront Advisers LLC acquired a new stake in BridgeBio Pharma in the 4th quarter valued at approximately $592,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.